OakChart

Verastem Inc

VSTMHealthcare·Biotechnology·USA·Small·NASD·Nov 11 • 12:36 PM ET

8.95+0.22 (2.53%)
2026-11-11 18:36 CET
Market cap
1,100.11 USD m
Revenue, TTM
100.30 USD m
Net income, TTM
-178.90 USD m
Free cash flow, TTM
-159.57 USD m
EPS diluted, TTM
-1.85
P/E
-
Compare

Price

VSTM against its 20, 50 and 200-day averages
2050200beatmiss
4.006.008.0010.0016.9M33.8MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26VSTMclose 8.9520-day 9.3950-day 8.47200-day 6.288.9552w low

17.3% under the 52-week high of 10.82 on 26 Nov 2025. 52-week low 3.43 on 25 Jun 2026. Last 15 sessions, 32.8% high to low

Profile

VSTM
52-week range, 75% of the way up
3.4310.82

Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.

IndexRUT
Employees102
IPOJan 27, 2012
Beta0.48
ATR, 14d0.66
Rel volume0.40
Short float17.24%
Insider own9.46%
Inst own75.78%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap1.13B
Enterprise Value1.08B
Income-178.90M
Sales100.30M
Book/sh0.11
Cash/sh1.37
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees102
IPOJan 27, 2012

Ratios

P/E-
Forward P/E-
PEG-
P/S11.25
P/B83.71
P/C6.53
P/FCF-
EV/EBITDA-
EV/Sales10.80
Quick Ratio1.91
Current Ratio1.93
Debt/Eq12.73
LT Debt/Eq11.51
Option/ShortYes / Yes

Earnings

EPS (ttm)-1.85
EPS next Y-2.04
EPS next Q-0.53
EPS this Y34.71%
EPS next Y-3.44%
EPS next 5Y11.44%
EPS past 3/5Y12.90% 10.63%
Sales past 3/5Y- 10.80%
EPS Y/Y TTM54.01%
Sales Y/Y TTM649.65%
EPS Q/Q45.19%
Sales Q/Q113.59%
EarningsNov 05 AMC
EPS/Sales Surpr.-56.45% -9.63%

Ownership

Insider Own9.46%
Insider Trans-0.62%
Inst Own75.78%
Inst Trans7.93%
ROA-88.02%
ROE-471.16%
ROIC-141.64%
Gross Margin86.11%
Oper. Margin-193.73%
Profit Margin-178.38%
SMA20-4.72%
SMA505.67%
SMA20042.63%
Trades-

Technical

Shs Outstand126.02M
Shs Float114.09M
Short Float17.24%
Short Ratio5.79
Short Interest19.67M
52W High10.82 -17.29%
52W Low3.43 160.95%
Volatility8.56% 9.32%
ATR (14)0.66
RSI (14)49.72
Beta0.48
Rel Volume0.40
Avg Volume3.40M
Volume681,751

Performance

Perf Week-9.13%
Perf Month20.14%
Perf Quarter34.19%
Perf Half Y89.63%
Perf YTD15.94%
Perf Year5.92%
Perf 3Y40.29%
Perf 5Y-74.54%
Perf 10Y-40.33%
Recom1.00
Target Price17.22
Prev Close8.73
Price8.95
Change %2.53%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Sep 17, 2026InitiatedWWolfe ResearchOutperform
Mar 12, 2026ResumedBBTIG ResearchBuy$19+112.3%
Feb 04, 2026InitiatedHH.C. WainwrightBuy$18+101.1%
Oct 16, 2025ResumedCCantor FitzgeraldOverweight
Apr 10, 2025InitiatedJJefferiesBuy$15+67.6%
Mar 24, 2025ReiteratedHH.C. WainwrightBuy$7 → $10+11.7%
Dec 31, 2024ReiteratedBBTIG ResearchBuy$13 → $20+123.4%
Sep 30, 2024InitiatedGGuggenheimBuy$13+45.2%
Nov 21, 2023ResumedBBTIG ResearchBuy$27+201.7%
Sep 27, 2023InitiatedRB. Riley SecuritiesBuy$21+134.6%

Peers

Mkt cap
TickerCompanyMkt cap
ERASErasca Inc5.93B
RVMDRevolution Medicines Inc39.52B
BBOTBridgeBio Oncology Therapeutics Inc200.03M
IMRXImmuneering Corp253.55M
CELCCelcuity Inc3.24B
KURAKura Oncology Inc695.95M
ORICORIC Pharmaceuticals Inc925.13M
ELVNEnliven Therapeutics Inc3.77B
ZNTLZentalis Pharmaceuticals Inc190.15M
CRDFCardiff Oncology Inc62.23M

Insider trading

latest 14 of 42
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Paterson DanPresident and CEONov 03 '26Sale9.601,29912,470651,413Nov 05 07:53 PM
Paterson DanPresident and CEOOct 01 '26Sale8.0044,121352,968652,712Oct 02 05:15 PM
Calkins DanielChief Financial OfficerOct 01 '26Sale8.002,56620,528123,781Oct 02 05:15 PM
Dan PatersonOfficer, DirectorOct 01 '26Proposed Sale8.0044,121353,047Oct 01 06:55 PM
Calkins DanielChief Financial OfficerSep 21 '26Sale7.7055424118,014Sep 23 08:10 PM
Paterson DanPresident and CEOAug 03 '26Sale5.811,3027,565589,940Aug 05 04:37 PM
Gagnon Robert E.DirectorJul 23 '26Proposed Sale5.8931,924188,032Jul 23 04:32 PM
Gagnon Robert E.DirectorJun 25 '26Proposed Sale4.2121,49290,481Jun 25 04:01 PM
Paterson DanPresident and CEOJun 22 '26Sale4.1820,87187,241591,242Jun 24 04:45 PM
Calkins DanielChief Financial OfficerJun 22 '26Sale4.184,08917,089117,238Jun 24 04:44 PM
Dan PatersonOfficer, DirectorJun 22 '26Proposed Sale4.1820,87187,241Jun 22 07:50 PM
Gagnon Robert E.DirectorMay 27 '26Proposed Sale4.3620,10387,649May 27 04:47 PM
Paterson DanPresident and CEOMay 04 '26Sale5.828064,691612,113May 06 04:01 PM
Paterson DanPresident and CEOFeb 04 '26Sale6.699706,489612,919Feb 05 04:10 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
XBIState Street SPDR S&P Biotech ETFAUM: 10.50B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
BBPVirtus Biotech ETFAUM: 135.69M
FESMFidelity Enhanced Small Cap Core ETFAUM: 6.82B
IDNAiShares Genomics Immunology and Healthcare ETFAUM: 354.14M
IWCiShares Micro-Cap ETFAUM: 1.22B

News

latest 14 of 206
  • Verastem Misses As Co-Pack Sales Stall, But VS-7375 Data And A $250 Million Raise Reset The Investment Case (Earnings Whispers) -10.34%
  • Verastem: Q3 Earnings Snapshot (Associated Press)
  • Verastem Oncology Reports Third Quarter 2026 Financial Results and Highlights Recent Business Updates (Business Wire)
  • Verastem Oncology to Participate in Upcoming November Investor Conferences (Business Wire)
  • Verastem Must Prove Its Commercial Rebound Is Real As G12D Hopes Lift The Stock (Earnings Whispers)
  • Loading…
  • Verastem Oncology to Report Third Quarter 2026 Financial Results on November 5, 2026 (Business Wire) +9.23%
  • VSTM Stock Clocks Best Day In 11 Months After Positive Cancer Drug Trial Update And Multiple Price-Target Hikes (Stocktwits) +19.71% -6.28%
  • Verastems KRAS inhibitor posts wins in mPDAC, mCRC and NSCLC (Clinical Trials Arena)
  • Verastem cancer drug shows early promise in small study (BioPharma Dive)
  • Verastem Is Getting a New CEO, $250 Million, and a Shot at Another Cancer Drug (Barrons.com)
  • Verastem Has Positive Early Cancer Data And $250M In New Funding: What VSTM Investors Need To Know (Stocktwits)
  • Verastem Oncology Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants (Business Wire)
  • Verastem Oncology Announces Planned Chief Executive Officer Transition and Succession Plan (Business Wire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-05-0.740-0.473-0.74024.0126.579
2026Q22026-08-06-0.350-0.431-0.34640.0822.888
2026Q12026-05-07-0.370-0.465-0.37218.6721.438
2025Q42026-03-04-0.390-0.520-0.39517.5416.907
2025Q32025-11-04-1.350-0.617-1.34711.245.769
2025Q22025-08-07-0.390-0.728-0.6252.141.259
2025Q12025-05-13-0.960-0.700-0.9620.160.109
2024Q42025-03-20-1.330-0.829-1.3250.000.208
2024Q32024-11-06-0.600-0.738-0.5950.070.069
2024Q22024-08-08-0.310-0.963-0.30710.000.078
2024Q12024-05-09-1.260-1.031-1.2620.000.007
2023Q42024-03-14-1.020-0.611-1.0210.007.127
2023Q32023-11-08-0.750-0.843-0.7470.000.037
2023Q22023-08-08-1.370-1.043-1.3690.000.026
2023Q12023-05-09-0.960-1.000-0.9400.000.026
2022Q42023-03-14-0.960-1.165-0.9860.000.005

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-24.000-23.790-24.00917.4616.41
2020FY-5.280-4.860-5.30088.5254.61
2021FY-4.920-4.760-4.8992.051.47
2022FY-4.560-4.711-4.5742.602.66
2023FY-3.960-3.144-3.9620.005.93
2024FY-3.660-3.031-3.65810.007.70
2025FY-3.020-3.210-3.02030.9130.25
2026FY--1.972--109.95
2027FY--2.040--146.02
2028FY--2.098--213.31
2029FY--1.365--330.05
2030FY--0.161--557.2

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-06100829.0825.1043.41
2026Q4S2026-11-05100431.1725.1043.41
2026Q4S2026-10-28100431.1725.1043.41
2026Q4S2026-10-27100431.1725.1043.41
2026Q4S2026-10-26100431.2125.1043.41
2026Q4S2026-10-21100431.2225.1043.41
2026Q4S2026-10-14101731.2225.1043.41
2026Q4S2026-10-13101632.6025.1043.41
2026Q4S2026-10-07102434.3629.1043.41
2026Q4S2026-09-15103334.5629.1043.41
2026Q4S2026-08-0793333.5729.1036.79
2026Q4S2026-08-0491232.5629.1034.70
2026Q4S2026-08-0392232.5629.1034.70
2026Q4S2026-07-2292332.5629.1034.70

Estimate history

EPS, annual-21.176-16.431-24.009-5.3-4.899-4.574-3.962-3.658-3.022-1.8514
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.595-1.325-0.962-0.625-1.347-0.395-0.372-0.346-0.738
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual026.71817.45618.5160.606001030.914100.3
Period201720182019202020212022202320242025TTM
Sales, quarterly0002.13711.24217.53518.67140.07824.012
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual4.2336.156.67614.20515.44116.71225.28144.78477.7494.469
Period201720182019202020212022202320242025MRQ
Shares, quarterly40.26244.78451.4961.52366.74977.7487.84390.48294.469
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue100.3030.9110.000.000.000.6118.5217.4626.72
Cost of Goods Sold Incl. D&A13.935.300.030.060.120.213.093.241.58
Gross Profit86.3725.629.97-0.06-0.120.4015.4314.2225.13
Selling, General and Administrative Excl. Other280.67195.75124.9392.0275.4263.2698.82146.56119.92
Research and Development180.04114.6081.3361.3650.5639.3540.8845.7843.65
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-194.31-170.13-114.96-92.08-75.53-62.86-83.39-132.34-94.78
Interest Expense1.371.144.564.142.149.9715.7920.615.81
Unusual Expense-13.5042.0714.96-2.750.000.006.36--
Net Income Before Taxes-178.09-209.47-130.45-87.37-73.81-71.20-67.53-149.21-72.43
Income Taxes0.820.000.180.000.000.000.190.000.00
Consolidated Net Income-178.90-209.47-130.64-87.37-73.81-71.20-67.73-149.21-72.43
Net Income From Continuing Operations-178.90-209.47-130.64-87.37-73.81-71.20-67.73-149.21-72.43
Net Income-178.90-209.47-130.64-87.37-73.81-71.20-67.73-149.21-72.43
EPS (Recurring)-1.86-2.60-3.36-4.05-4.57-4.90-4.95-24.01-16.43
EPS (Basic, Before Extraordinaries)-1.85-3.02-3.66-3.96-4.57-4.90-5.30-24.01-13.38
EPS (Diluted)-1.85-3.02-3.66-3.96-4.57-4.90-5.30-24.01-16.43
EBITDA-193.17-169.40-114.93-92.02-75.42-62.65-82.07-130.34-93.36
Non-Operating Income (Expense)4.093.874.036.113.861.6338.023.7428.16
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense9.719.405.805.866.057.715.938.546.67
Price To Sales Ratio8.1317.3118.46--589.9917.645.728.72
Gross Margin86.1182.8699.74--66.0183.3281.4694.07
Operating Margin-193.73-550.33-1,149.56---10,372.28-450.38-758.14-354.75
Net Margin-178.38-677.59-1,306.37---11,749.17-365.77-854.77-271.11
Shares Outstanding94.4777.7444.7825.2816.7115.4414.206.686.15
Market Capitalization1,100.111,100.11230.10205.6884.56379.84363.07107.36247.99

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue24.0140.0818.6717.5411.242.140.000.00
Cost of Goods Sold Incl. D&A3.944.043.052.891.960.570.010.01
Gross Profit20.0736.0415.6214.649.281.56-0.01-0.01
Selling, General and Administrative Excl. Other95.2968.7560.5256.1250.0045.3344.1631.58
Research and Development68.8141.3438.2231.6828.9924.7929.1520.81
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-75.22-32.71-44.90-41.47-40.72-43.76-44.17-31.59
Interest Expense0.210.360.380.410.320.210.191.15
Unusual Expense-0.001.84-7.45-7.8958.63-17.338.6632.61
Net Income Before Taxes-74.72-33.86-36.59-32.92-98.52-25.93-52.10-64.36
Income Taxes0.000.820.000.000.000.000.000.18
Consolidated Net Income-74.72-34.67-36.59-32.92-98.52-25.93-52.10-64.55
Net Income From Continuing Operations-74.72-34.67-36.59-32.92-98.52-25.93-52.10-64.55
Net Income-74.72-34.67-36.59-32.92-98.52-25.93-52.10-64.55
EPS (Recurring)-0.74-0.33-0.43-0.46-0.79-0.79-0.85-0.86
EPS (Basic, Before Extraordinaries)-0.74-0.35-0.37-0.39-1.35-0.39-0.96-1.33
EPS (Diluted)-0.74-0.35-0.37-0.39-1.35-0.62-0.96-1.33
EBITDA-74.94-32.43-44.62-41.18-40.42-43.64-44.16-31.58
Non-Operating Income (Expense)0.711.061.241.081.150.710.920.98
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense2.932.712.052.032.183.411.791.60
Price To Sales Ratio8.134.3710.5120.8348.28143.7832.6725.18
Gross Margin83.5789.9283.6683.5182.5773.14--
Operating Margin-313.28-81.62-240.46-236.52-362.17-2,047.92--
Net Margin-311.19-86.51-195.98-187.72-876.34-1,213.57--
Shares Outstanding94.4790.4887.8477.7466.7561.5251.4944.78
Market Capitalization1,100.11335.68465.53581.47543.45228.04310.46230.10

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments204.9988.82138.0687.89100.26141.2375.51250.3986.83
Short Term Receivables9.210.200.040.130.720.242.520.310.00
Inventories1.830.000.000.000.000.003.100.330.00
Other Current Assets7.385.945.584.854.773.473.832.230.95
Total Current Assets223.4194.96143.6892.87105.74144.9484.96253.2687.79
Net Property, Plant & Equipment0.491.441.211.882.513.144.021.370.86
Total Investments and Advances0.000.240.240.240.246.0435.040.000.00
Intangible Assets16.43----0.0020.0121.580.00
Other Assets6.114.904.590.060.170.231.011.031.14
Total Assets246.44101.54149.7295.05108.66154.35145.05277.2489.79
Short Term Debt Incl. Current Port. of LT Debt5.840.990.941.070.670.560.425.720.00
Accounts Payable12.454.037.184.902.301.889.6510.259.19
Other Current Liabilities53.9825.9518.2515.6915.6214.6619.8221.117.94
Total Current Liabilities72.2730.9726.3821.6618.5917.0929.8937.0817.13
Long Term Debt81.3341.2640.6226.002.5121.98107.11114.7414.83
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Other Liabilities35.6558.204.190.000.000.000.871.120.15
Total Liabilities189.25130.4371.1947.6621.1039.08137.87152.9432.11
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.0021.160.000.000.000.000.000.00
Common Equity57.20-28.8957.3747.3987.56115.277.17124.3057.68
Total Shareholders Equity57.20-28.8978.5347.3987.56115.277.17124.3057.68
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity57.20-28.8978.5347.3987.56115.277.17124.3057.68
Total Liabilities & Stockholders Equity246.44101.54149.7295.05108.66154.35145.05277.2489.79
Book Value Per Share0.74-0.652.272.845.678.121.0720.2113.63
Tangible Book Value Per Share0.52-0.652.272.845.678.12-1.9216.7013.63
Full-Time Employees1027873574848135169169
Price to Book Ratio81.6518.822.471.344.343.1514.962.002.99
Return on Assets-120.39-103.99-71.39-72.47-54.14-45.24-70.67-39.47-78.19
Return on Equity-1,480.15-526.34-138.76-109.39-70.21-110.62-226.98-79.61-104.33
Return on Invested Capital-151.21-1,056.42-73.33-100.58-79.05-49.34-130.56-30.30-93.50
Quick Ratio3.073.075.454.295.698.482.746.825.13
Current Ratio3.093.075.454.295.698.482.846.835.13

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-178.90-209.47-130.64-87.37-73.81-71.20-67.73-149.21-72.43
Depreciation1.140.730.030.060.120.211.322.001.42
Other Funds (Non Cash)-9.7245.2322.121.806.1216.9119.5016.05-17.15
Funds from Operations-187.48-163.51-108.49-85.50-67.57-54.09-46.90-131.16-88.17
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital27.9126.003.72-0.963.900.5811.63-7.8013.65
Cash from Operating Activities-159.57-137.51-104.77-86.46-63.67-53.50-35.27-138.96-74.52
Capital Expenditures-8.85-9.62-0.030.000.00-0.20-0.03-0.01-23.51
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00-
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.000.08
Purchase or Sale of Investments0.230.0060.00-44.4566.190.28-47.3389.62-114.95
Purchase of Investments-16.020.000.00-96.45-17.82-86.44-79.38-94.12-125.45
Sale Or Maturity of Investments16.250.0060.0052.0084.0086.7232.05183.7410.50
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-8.61-9.6259.97-44.4566.190.09-47.3689.61-138.38
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock157.21230.8854.93119.5827.647.81109.040.57105.97
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock157.21230.8854.93119.5827.647.81109.040.57105.97
Proceedsfrom Stock Options156.93230.7754.69119.5227.356.72106.060.00105.16
Issuance or Reduction of Debt, Net46.0632.42-0.1514.6224.150.00-37.37-2.50155.20
Change in Long Term Debt46.0632.42-0.1514.6224.150.00-37.37-2.50155.20
Issuance of Long Term Debt50.7476.181.3016.3524.150.000.009.67155.20
Reduction of Long Term Debt-4.67-43.76-1.45-1.730.000.00-37.37-12.170.00
Net Financing Active Other Cash Flow0.000.000.000.000.00-0.93-0.28-0.070.00
Other Financing Activities Uses0.000.000.000.000.00-0.93-0.28-0.070.00
Cash from Financing Activities203.28263.3154.78134.1951.786.8871.39-2.00261.16
Net Change in Cash35.09116.179.983.2954.30-46.53-11.24-51.3548.27
Free Cash Flow-159.57-137.51-104.80-86.46-63.67-53.70-35.30-138.96-76.02
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments172.80136.35181.68204.99137.71164.32
Short Term Receivables10.0729.0710.369.216.922.28
Inventories2.252.402.291.831.791.17
Other Current Assets14.258.338.587.387.646.51
Total Current Assets199.38176.16202.90223.41154.06174.27
Net Property, Plant & Equipment2.462.622.790.490.750.98
Total Investments and Advances0.240.240.240.000.000.00
Intangible Assets15.5915.8716.1516.4316.7015.64
Other Assets11.9811.625.726.115.345.37
Total Assets229.64206.51227.81246.44176.85196.26
Short Term Debt Incl. Current Port. of LT Debt12.355.936.295.845.104.18
Accounts Payable20.2318.009.6012.459.898.05
Other Current Liabilities70.7554.2050.9553.9844.7238.14
Total Current Liabilities103.3378.1366.8472.2759.7150.36
Long Term Debt116.2178.3979.1981.3384.3780.54
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.0035.6548.2929.31
Total Liabilities219.54156.53146.03189.25192.38160.21
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity10.1049.9981.7857.20-15.5336.06
Total Shareholders Equity10.1049.9981.7857.20-15.5336.06
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity10.1049.9981.7857.20-15.5336.06
Total Liabilities & Stockholders Equity229.64206.51227.81246.44176.85196.26
Book Value Per Share0.110.550.930.74-0.230.59
Tangible Book Value Per Share-0.060.380.750.52-0.480.33
Full-Time Employees---102--
Price to Book Ratio81.654.107.20-33.1915.07-6.59
Return on Assets-88.02-100.65-107.90-120.39-159.02-110.30
Return on Equity--471.16-786.15-1,480.15-2,888.70-437.92
Return on Invested Capital-59.16-27.01-22.73-23.76-143.09-22.24
Quick Ratio1.912.223.003.072.553.44
Current Ratio1.932.253.043.092.583.46

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-74.72-34.67-36.59-32.92-98.52-25.93
Depreciation0.280.280.280.300.290.13
Other Funds (Non Cash)1.753.36-7.24-7.5959.15-15.48
Funds from Operations-72.69-31.04-43.55-40.21-39.08-41.28
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital39.10-12.87-8.5710.252.868.62
Cash from Operating Activities-33.59-43.91-52.12-29.95-36.22-32.66
Capital Expenditures-7.500.000.00-1.34-8.280.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.0016.25-16.020.000.000.00
Purchase of Investments0.000.00-16.020.000.000.00
Sale Or Maturity of Investments0.0016.250.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-7.5016.25-16.02-1.34-8.280.00
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock29.000.0329.4198.7718.1679.69
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock29.000.0329.4198.7718.1679.69
Proceedsfrom Stock Options28.800.0029.3798.7518.0879.69
Issuance or Reduction of Debt, Net48.54-1.56-0.72-0.19-0.28-0.27
Change in Long Term Debt48.54-1.56-0.72-0.19-0.28-0.27
Issuance of Long Term Debt50.000.000.740.000.000.00
Reduction of Long Term Debt-1.46-1.56-1.46-0.19-0.28-0.27
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities77.54-1.5428.6998.5817.8879.42
Net Change in Cash36.45-29.20-39.4467.28-26.6246.75
Free Cash Flow-33.59-43.91-52.12-29.95-36.22-32.66

Revenue breakdown

Product revenue, net2025: 30.91M
Sale of COPIKTRA license and related assets2024: 10.00M
United States2024: 10.00M 2025: 30.91M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3017.24%19.7M114.1M3.27M
2026-10-1515.64%17.2M110.0M2.99M
2026-09-3018.30%15.0M81.8M2.28M
2026-09-1522.05%18.0M81.8M2.49M
2026-08-3122.38%18.3M81.8M2.44M
2026-08-1423.13%18.9M81.8M2.52M
2026-07-3123.73%19.8M83.5M2.62M
2026-07-1525.34%20.1M79.3M2.61M
2026-06-3030.43%24.1M79.3M2.46M
2026-06-1527.46%21.8M79.3M2.33M
2026-05-2925.91%21.2M81.9M2.21M
2026-05-1521.73%17.9M82.2M2.10M
2026-04-3023.24%17.5M75.4M1.95M
2026-04-1523.11%17.4M75.4M1.89M
2026-03-3121.73%16.4M75.3M1.97M
2026-03-1323.70%17.9M75.3M1.79M
2026-02-2726.47%17.1M64.6M1.76M
2026-02-1327.95%18.1M64.6M2.01M
2026-01-3025.34%16.5M65.0M2.16M
2026-01-1526.24%17.1M65.2M2.34M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call1.005.5010.307.170.0002.000.000.991-0.0140.000
call2.004.509.300.000.0000.000.000.986-0.0150.000
call3.003.508.305.9020.4126.000.000.980-0.0150.001
call4.002.507.300.0014.0930.000.000.973-0.0150.001
call5.001.506.303.8210.5801.000.000.965-0.0140.001
call6.000.705.302.658.9485.000.000.953-0.0130.001
call7.000.004.502.457.41251.000.000.931-0.0120.002
call8.000.001.201.151.15913910.000.779-0.0250.004
call9.000.250.600.431.1151,3750.000.569-0.0740.006
call10.000.050.150.200.86767210.000.227-0.0210.004
call11.000.000.200.051.3822900.000.202-0.0310.004
call12.000.000.400.311.7589.000.000.172-0.0350.004
call13.000.002.550.001.8650.000.000.129-0.0310.003
call14.000.002.550.102.1126.000.000.118-0.0330.003
call15.000.002.550.052.3333.000.000.110-0.0340.003
call16.000.002.550.002.5340.000.000.103-0.0360.003
call17.000.002.550.002.7180.000.000.098-0.0370.002
call18.000.002.550.002.8880.000.000.094-0.0380.002
call19.000.002.550.003.0450.000.000.091-0.0390.002
put1.000.000.050.007.5240.000.00-0.009-0.0130.000
put2.000.002.550.005.3660.000.00-0.014-0.0150.000
put3.000.000.100.003.7460.000.00-0.020-0.0130.001
put4.000.000.200.052.82020.000.00-0.027-0.0130.001
put5.000.000.300.052.10462.000.00-0.037-0.0120.001
put6.000.000.450.051.51121.000.00-0.050-0.0110.001
put7.000.000.050.051.86897.00100-0.157-0.0350.003
put8.000.050.200.161.03735650.00-0.221-0.0240.004
put9.000.303.200.703.8434560.00-0.431-0.0730.006
put10.000.002.151.102.6711070.00-0.773-0.0200.004
put11.000.404.700.005.9070.000.00-0.801-0.0300.004
put12.001.005.500.005.9690.000.00-0.828-0.0330.004
put13.002.006.500.006.4350.000.00-0.845-0.0360.003
put14.003.007.500.006.7610.000.00-0.858-0.0380.003
put15.004.008.500.007.0060.000.00-0.867-0.0400.003
put16.006.409.500.007.2700.000.00-0.875-0.0420.003
put17.006.0010.500.007.5370.000.00-0.880-0.0430.003
put18.007.0011.500.007.7810.000.00-0.885-0.0440.003
put19.009.4012.500.007.9360.000.00-0.889-0.0450.003

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-10SCHEDULE 13GSEC
2026-11-054Statement of changes in beneficial ownership of securities2026-11-03SEC
2026-11-05S-3ASRAutomatic shelf registration statement of securities of well-known seasoned issuersSEC
2026-11-05S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-11-058-KCurrent report2026-11-05SEC
2026-11-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-10-30SCHEDULE 13G/ASEC
2026-10-148-KCurrent report2026-10-14SEC
2026-10-14424B5SEC
2026-10-14424B5SEC
2026-10-148-KCurrent report2026-10-12SEC
2026-10-024Statement of changes in beneficial ownership of securities2026-09-30SEC
2026-10-024Statement of changes in beneficial ownership of securities2026-09-30SEC
2026-10-01144Filing for proposed sale of securities under Rule 144.SEC
2026-09-234Statement of changes in beneficial ownership of securities2026-09-21SEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-078-KCurrent report2026-08-06SEC
2026-08-07SCHEDULE 13GSEC
2026-08-068-KCurrent report2026-08-06SEC
2026-08-0610-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-054Statement of changes in beneficial ownership of securities2026-08-03SEC
2026-07-31SCHEDULE 13GSEC
2026-07-30SCHEDULE 13G/ASEC
2026-07-23144Filing for proposed sale of securities under Rule 144.SEC
2026-07-08SCHEDULE 13G/ASEC
2026-06-25144Filing for proposed sale of securities under Rule 144.SEC
2026-06-244Statement of changes in beneficial ownership of securities2026-06-22SEC
2026-06-244Statement of changes in beneficial ownership of securities2026-06-22SEC
2026-06-238-KCurrent report2026-06-23SEC
2026-06-22144Filing for proposed sale of securities under Rule 144.SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110012.47K1
2026-1000373.50K2
2026-09004241
2026-08007.56K1
2026-070000
2026-0600104.33K2
2026-05004.69K1
2026-040000
2026-030000
2026-02006.49K1
2026-0100109.98K2
2025-1200196.50K13
2025-1100282.37K8

Institutional holders

Manager% owned
BlackRock, Inc.10.46%
Nantahala Capital Management, LLC8.16%
ARMISTICE CAPITAL, LLC7.99%
RTW INVESTMENTS, LP7.55%
Deep Track Capital, LP6.53%
STATE STREET CORP5.84%
Rosalind Advisors, Inc.4.54%
VANGUARD CAPITAL MANAGEMENT LLC4.38%
Stonepine Capital Management, LLC3.81%
VANGUARD PORTFOLIO MANAGEMENT LLC3.72%

Funds

Fund% owned
State Street(R) SPDR(R) S&P(R) Biotech ETF3.86%
VANGUARD TOTAL STOCK MARKET INDEX FUND3.20%
iShares Russell 2000 ETF2.35%
VANGUARD EXPLORER FUND1.59%
VANGUARD EXTENDED MARKET INDEX FUND1.09%
Fidelity Small Cap Index Fund0.99%
BlackRock Advantage Small Cap Core Fund0.90%
iShares Russell 2000 Growth ETF0.85%
Fidelity Enhanced Small Cap Core ETF0.66%
VANGUARD STRATEGIC SMALL-CAP EQUITY FUND0.61%

OakChart. VSTM. Cached 15 minutes.